

HENRY SCHEIN INC  
Form 8-K  
October 20, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 14, 2011**

**Henry Schein, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-27078**  
(Commission File Number)

**11-3136595**  
(I.R.S. Employer  
Identification No.)

**135 Duryea Road, Melville, New York**  
(Address of principal executive offices)

**11747**  
(Zip Code)

Registrant's telephone number, including area code: **(631) 843-5500**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

On October 14, 2011, Henry Schein, Inc. (the Company ) entered into an amendment (the Amendment ) to its Distribution Agreement for Fluviral® Influenza Vaccine, dated as of December 2, 2004, with ID Biomedical Corporation of Quebec (successor in interest to ID Biomedical Corporation) ( IDB ), as amended (the Distribution Agreement ), to terminate the Distribution Agreement solely with respect to the 2012/2013 Flu Season. Pursuant to the Amendment, the Distribution Agreement will automatically terminate at the conclusion of the 2011/2012 Flu Season.

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 1.1 and is incorporated herein by reference.

**Item 8.01. Other Events**

The Company has arrangements with other manufacturers, including a new distribution agreement entered into October 20, 2011, to distribute influenza vaccine for the 2012/2013 flu season. The term of this new agreement is from January 1 to December 31, 2012, with an option to renew for one year upon the mutual agreement of the parties. The Company will notify this manufacturer in advance of the flu season of its required volume of doses, and the pricing will be determined based on volume.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits:

- 1.1 Amendment dated October 14, 2011 to Distribution Agreement, dated as of December 2, 2004, by and between Henry Schein, Inc. and ID Biomedical Corporation of Quebec (successor in interest to ID Biomedical Corporation).
-

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HENRY SCHEIN, INC.**

(Registrant)

Date: October 20, 2011

By: /s/ Michael S. Ettinger  
Michael S. Ettinger  
Senior Vice President and General  
Counsel

---

**EXHIBIT INDEX**

**Exhibit**

- 1.1 Amendment dated October 14, 2011 to Distribution Agreement, dated as of December 2, 2004, by and between Henry Schein, Inc. and ID Biomedical Corporation of Quebec (successor in interest to ID Biomedical Corporation).